Effects of differences in serum total homocysteine, folate, and vitamin B12 on cognitive impairment in stroke patients

详细信息    查看全文

• 作者：Bo Jiang (1)
  Yumei Chen (1)
  Guoen Yao (1)
  Cunshan Yao (1)
  Hongmei Zhao (1)
  Xiangdong Jia (1)
  Yunyan Zhang (1)
  Junling Ge (1)
  Enchao Qiu (1)
  Chengyun Ding (1)
  
  1. Department of Neuromedical Center ; The First Hospital Affiliated to the Chinese PLA General Hospital ; 51 Fucheng Avenue ; Beijing ; 100048 ; Haidian District ; China
  
• 关键词：Cognitive impairment ; Cerebrovascular disorder ; Neuropsychology ; Event related potentials P300 ; Homocysteine
• 刊名：BMC Neurology
• 出版年：2014
• 出版时间：December 2014
• 年：2014
• 卷：14
• 期：1
• 全文大小：181 KB
• 参考文献：1. Moorhouse, P, Rockwood, K (2008) Vascular cognitive impairment: current concepts and clinical developments. Lancet Neurol 7: pp. 246-255 CrossRef
  2. Serrano, S, Domingo, J, Rodr铆guez-Garcia, E, Castro, MD, Ser, T (2007) Frequency of cognitive impairment without dementia in patients with stroke: a two-year follow-up study. Stroke 38: pp. 105-110 CrossRef
  3. Stephan, BC, Matthews, FE, Khaw, KT, Dufouil, C, Brayne, C (2009) Beyond mild cognitive impairment: vascular cognitive impairment, no dementia (VCIND). Alzheimers Res Ther 1: pp. 4 CrossRef
  4. Manolescu, BN, Oprea, E, Farcasanu, IC, Berteanu, M, Cercasov, C (2010) Homocysteine and vitamin therapy in stroke prevention and treatment: a review. Acta Biochim Pol 57: pp. 467-477
  5. Sala, I, Bel茅n S谩nchez-Saudin贸s, M, Molina-Porcel, L, L谩zaro, E, Gich, I, Clarim贸n, J, Blanco-Vaca, F, Blesa, R, G贸mez-Isla, T, Lle贸, A (2008) Homocysteine and cognitive impairment. relation with diagnosis and neuropsychological performance. Dement Geriatr Cogn Disord 26: pp. 506-512 CrossRef
  6. Rom谩n, GC, Sachdev, P, Royall, DR, Bullock, RA, Orgogozo, JM, L贸pez-Pousa, S, Arizaga, R, Wallin, A (2004) Vascular cognitive disorder: a new diagnostic category updating vascular cognitive impairment and vascular dementia. J Neurol Sci 226: pp. 81-87 CrossRef
  7. Rockwood, K, Howard, K, MacKnight, C, Darvesh, S (1999) Spectrum of disease in Vascular cognitive impairment. Neuroepidemiology 18: pp. 248-254 CrossRef
  8. Olsen, TS, Langhorne, P, Diener, HC, Hennerici, M, Ferro, J, Sivenius, J, Wahlgren, NG, Bath, P (2003) European stroke initiative recommendations for stroke management-update 2003. Cerebrovasc Dis 16: pp. 311-337 CrossRef
  9. Karunaratne, S, Hanwella, R, Silva, V (2011) Validation of the sinhala version of the montreal cognitive assessment in screening for dementia. Ceylon Med J 56: pp. 147-153 CrossRef
  10. Refsum, H, Smith, AD, Ueland, PM, Nexo, E, Clarke, R, McPartlin, J, Johnston, C, Engbaek, F, Schneede, J, McPartlin, C, Scott, JM (2004) Facts and recommendations about total homocysteine determinations: an expert opinion. Clin Chem 50: pp. 3-32 CrossRef
  11. Herrmann, W, Obeid, R (2011) Homocysteine: a biomarker in neurodegenerative diseases. Clin Chem Lab Med 49: pp. 435-441
  12. Ford, AH, Flicker, L, Singh, U, Hirani, V, Almeida, OP (2013) Homocysteine, depression and cognitive function in older adults. J Affect Disord 151: pp. 646-651 CrossRef
  13. Budge, M, Johnston, C, Hogervorst, E, Jager, C, Milwain, E, Iversen, SD, Barnetson, L, King, E, Smith, AD (2000) Plasma total homocysteine and cognitive performance in a volunteer elderly population. Ann N Y Acad Sci 903: pp. 407-410 CrossRef
  14. Ashjazadeh, N, Fathi, M, Shariat, A (2013) Evaluation of homocysteine level as a risk factor among patients with ischemic stroke and its subtypes. Iran J Med Sci 38: pp. 233-239
  15. McNulty, H, Strain, JJ, Pentieva, K, Ward, M (2012) C(1) metabolism and CVD outcomes in older adults. Proc Nutr Soc 71: pp. 213-221 CrossRef
  16. Kim, G, Kim, H, Kim, KN, Son, JI, Kim, SY, Tamura, T, Chang, N (2013) Relationship of cognitive function with B vitamin status, homocysteine, and tissue factor pathway inhibitor in cognitively impaired elderly: a cross-sectional survey. J Alzheimers Dis 33: pp. 853-862
  17. Douaud, G, Refsum, H, Jager, CA, Jacoby, R, Nichols, TE, Smith, SM, Smith, AD (2013) Preventing Alzheimer鈥檚 disease-related gray matter atrophy by B-vitamin treatment. Proc Natl Acad Sci U S A 110: pp. 9523-9528 CrossRef
  18. Rodriguez-Oroz, MC, Lage, PM, Sanchez-Mut, J, Lamet, I, Pagonabarraga, J, Toledo, JB, Garc铆a-Garcia, D, Clavero, P, Samaranch, L, Irurzun, C, Matsubara, JM, Irigoien, J, Bescos, E, Kulisevsky, J, P茅rez-Tur, J, Obeso, JA (2009) Homocysteine and cognitive impairment in Parkinson鈥檚 disease: a biochemical, neuroimaging, and genetic study. Mov Disord 24: pp. 1437-1444 CrossRef
  19. Bangen, KJ, Beiser, A, Delano-Wood, L, Nation, DA, Lamar, M, Libon, DJ, Bondi, MW, Seshadri, S, Wolf, PA, Au, R (2013) APOE Genotype modifies the relationship between midlife vascular risk factors and later cognitive decline. J Stroke Cerebrovasc Dis 22: pp. 1361-1369 CrossRef
  20. Folin, M, Baiguera, S, Gallucci, M, Conconi, MT, Liddo, R, Zanardo, A, Parnigotto, PP (2005) A cross-sectional study of homocysteine, NO-levels, and CT-findings in Alzheimer dementia, vascular dementia and controls. Biogerontology 6: pp. 255-260 CrossRef
  21. Troen, AM, Shea-Budgell, M, Shukitt-Hale, B, Smith, DE, Selhub, J, Rosenberg, IH (2008) B-vitamin deficiency causes hyperhomocysteinemia and vascular cognitive impairment in mice. Proc Natl Acad Sci U S A 105: pp. 12474-12479 CrossRef
  22. Zhuo, JM, Portugal, GS, Kruger, WD, Wang, H, Gould, TJ, Pratico, D (2010) Diet-induced hyperhomocysteinemia increases amyloid-beta formation and deposition in a mouse model of Alzheimer鈥檚 disease. Curr Alzheimer Res 7: pp. 140-149 CrossRef
  23. McMahon, JA, Green, TJ, Skeaff, CM, Knight, RG, Mann, JI, Williams, SM (2006) A controlled trial of homocysteine lowering and cognitive performance. N Engl J Med 354: pp. 2764-2772 CrossRef
  24. Viswanathan, A, Raj, S, Greenberg, SM, Stampfer, M, Campbell, S, Hyman, BT, Irizarry, MC (2009) Plasma abeta, homocysteine, and cognition: the Vitamin Intervention for Stroke Prevention (VISP) trial. Neurology 72: pp. 268-272 CrossRef
  25. Abla, D, Katahira, K, Okanoya, K (2008) On-line assessment of statistical learning by event-related potentials. J Cogn Neurosci 20: pp. 952-964 CrossRef
  26. Ivica, N, Titlic, M, Pavelin, S (2013) P300 wave changes in patients with multiple sclerosis. Acta Inform Med 21: pp. 205-207 CrossRef
  27. Medvidovic, S, Titlic, M, Maras-Simunic, M (2013) P300 evoked potential in patients with mild cognitive impairment. Acta Inform Med 21: pp. 89-92 CrossRef
  28. Braverman, ER, Chen, TJ, Prihoda, TJ, Sonntag, W, Meshkin, B, Downs, BW, Mengucci, JF, Blum, SH, Notaro, A, Arcuri, V, Varshavskiy, M, Blum, K (2007) Plasma growth hormones, P300 event-related potential and test of variables of attention (TOVA) are important neuroendocrinological predictors of early cognitive decline in a clinical setting: evidence supported by structural equation modeling (SEM) parameter estimates. Age (Dordr) 29: pp. 55-67 CrossRef
  29. Park, EJ, Han, SI, Jeon, YW (2010) Auditory and visual P300 reflecting cognitive improvement in patients with schizophrenia with quetiapine: a pilot study. Prog Neuropsychopharmacol Biol Psychiatry 34: pp. 674-680 CrossRef
  
• 刊物主题：Neurology; Neurochemistry; Neurosurgery;
• 出版者：BioMed Central
• ISSN：1471-2377

文摘

Background Vascular cognitive impairment-no dementia (VCIND) refers to the early or mild cognitive impairment induced by cerebral vascular injury. Research shows that serum total homocysteine (tHcy) level is an independent risk factor for cerebral vascular disease and may be closely related to cognitive function.Current studies on the tHcy level in VCIND patients are limited, and the relationship of tHcy with cognitive function remains unclear. This study aims to investigate the tHcy levels in patients with VCIND and to determine their correlation with cognitive function, as well as to provide useful clues for preventing and treating VCIND. Methods The tHcy, folate, and vitamin B12 levels in 82 patients with VCIND were reviewed retrospectively and compared with those of 80 stroke patients without cognitive impairment and 69 healthy controls by using the Montreal Cognitive Assessment (MoCA) scale and the event-related potential P300 to evaluate cognitive function. Results The tHcy levels in the VCIND group were higher than those in the other two groups, whereas the folate and Vitamin B12 levels in the VCIND group were lower than those of the other two groups. The tHcy levels in the stroke group were higher than those in the control group, and the folate and vitamin B12 levels in the stroke group were lower than those in the control group. The patients in the VCIND group with high tHcy exhibited lower MoCA scores and prolonged P300 latency than those in with normal tHcy. Correlation analysis showed that tHcy level is positively correlated with P300 latency period and negatively correlated with MoCA score. Conclusion The tHcy levels were significantly higher and the vitamin B12 and folate levels were significantly lower in the patients with VCIND than those in the other groups. The high tHcy levels in the VCIND patients may be correlated with impaired cognitive function.